Overview

Vernalis Therapeutics, Inc. was established to distribute prescription pharmaceuticals into the US market.  Our parent company, Vernalis plc, is a UK based company listed on AIM.  The VTI activities were founded on the development and licensing agreement with Tris Pharma, Inc. but the group has subsequently added Moxatag® to the commercial portfolio.

Latest News

Unaudited Interim Results for the six months ended 31 December 2016

Vernalis plc (LSE: VER) today announces its unaudited consolidated results for the six month period ended 31 December 2016.

Read more ...

Fact Sheet

For more information on Vernalis, click below to download a copy of our fact sheet

 

Factsheet-Nov14

 

 

 

 

Contact Vernalis Therapeutics

T: 1-484-913-0700
F: 1-610-651 5976

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch